OraSure Technologies (NASDAQ:OSUR) Cut to “Hold” at StockNews.com

StockNews.com cut shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a report published on Thursday.

OraSure Technologies Price Performance

OraSure Technologies stock opened at $3.93 on Thursday. OraSure Technologies has a 12 month low of $3.52 and a 12 month high of $8.04. The company has a market cap of $293.15 million, a price-to-earnings ratio of 26.20 and a beta of 0.05. The stock’s 50-day moving average is $3.81 and its 200-day moving average is $4.04.

Institutional Investors Weigh In On OraSure Technologies

Several large investors have recently made changes to their positions in OSUR. Renaissance Technologies LLC lifted its holdings in shares of OraSure Technologies by 23.1% during the 4th quarter. Renaissance Technologies LLC now owns 2,774,443 shares of the medical instruments supplier’s stock valued at $10,016,000 after acquiring an additional 521,400 shares in the last quarter. Archon Capital Management LLC boosted its position in shares of OraSure Technologies by 145.1% in the fourth quarter. Archon Capital Management LLC now owns 827,777 shares of the medical instruments supplier’s stock worth $2,988,000 after buying an additional 490,034 shares during the period. Peapod Lane Capital LLC purchased a new stake in shares of OraSure Technologies in the fourth quarter worth about $1,730,000. American Century Companies Inc. grew its stake in shares of OraSure Technologies by 11.4% in the fourth quarter. American Century Companies Inc. now owns 2,345,837 shares of the medical instruments supplier’s stock valued at $8,468,000 after buying an additional 240,224 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of OraSure Technologies by 66.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 524,950 shares of the medical instruments supplier’s stock valued at $2,242,000 after buying an additional 209,580 shares during the period. Institutional investors and hedge funds own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.